Research programme: anti-infectives - AureoGen Biosciences/Merck
Latest Information Update: 28 Mar 2020
At a glance
- Originator AureoGen Biosciences
- Developer Merck & Co
- Class Anti-infectives; Antifungals; Cyclic peptides
- Mechanism of Action Inositol phosphorylceramide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Infections; Mycoses
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Infections in USA
- 28 Mar 2020 No recent reports of development identified for research development in Mycoses in USA
- 24 Feb 2016 Early research in Infections in USA (unspecified route)